Serum amyloid A, C-reactive protein and remnant-like lipoprotein particle cholesterol in type 2 diabetic patients with coronary heart disease

Annals of Clinical Biochemistry

Volumn 41, Issue 2, 2004, Pages 125-129

  Hamano, M ^a   Saito, M ^a   Eto, M ^a   Nishimatsu, S ^a   Suda, H ^b   Matsuda, M ^a   Matsuki, M ^a   Yamamoto, S ^a   Kaku, K ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b DAIICHI Clinical Laboratories Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRIC ACID DERIVATIVE; INSULIN; LIPOPROTEIN; ORAL ANTIDIABETIC AGENT; REMNANT LIKE LIPOPROTEIN PARTICLE CHOLESTEROL; SERUM AMYLOID A; STATINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOADSORPTION; IMMUNOASSAY; INFLAMMATION; ISCHEMIC HEART DISEASE; LATEX AGGLUTINATION TEST; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LATEX FIXATION TESTS; LIPOPROTEINS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; SERUM AMYLOID A PROTEIN; TRIGLYCERIDES;

EID: 1942502198     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/000456304322880005     Document Type: Article

References (33)

1. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-11
2. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43
3. Packard CJ. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 2000; 343: 1148-55
4. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-26
5. Schalkwijk CG, W Poland DC, von Dijk W, et al. Plasma concentration of C-reactive protein is increased in type 1 diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42: 351-7
6. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int 2000; 58: 1703-10
7. Yudkin JS, Panahloo A, Stehouwer C, et al. The influence of improved glycemic control with insulin and sulphonylureas on acute phase and endothelial markers in type 2 diabetic subjects. Diabetologia 2000; 43: 1099-106
8. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC. Serum amyloid A-containing human high density lipoprotein 3. Density, size and apolipoprotein composition. J Biol Chem 1986; 261: 9644-65
9. Yamada T. Serum amyloid A (SAA): a concise review of biology, assays methods and clinical significance. Clin Chem Lab Med 1999; 37: 381-8
10. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204
11. Fyle AL, Rothenberg LS, de Beer FC, Cantor RM, Rotter JI, Lusis AJ. Association between serum amyloid A protein and coronary artery disease: evidence from two distinct atherosclerotic processes. Circulation 1997; 96: 2914-19
12. Kumon Y, Suehiro T, Itahara T, Ikeda Y, Hashimoto K. Serum amyloid A protein in patients with non-insulin-dependent diabetes mellitus. Clin Biochem 1994; 27: 469-73
13. Sakata-Kaneko S, Wakatsuki Y, Usui T, et al. Lysophosphatidylcholine upregulates CD40 ligand expression in newly activated human CD4+ T cells. FEBS Lett 1998; 433: 161-5
14. Bierman EL. Atherogenesis in diabetes. Arterioscler Thromb 1992; 12: 647-56
15. Nakajima K, Saito T, Tamura A, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-1 immunoaffinity mixed gels. Clin Chim Acta 1993; 223: 53-71
16. Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody apolipoprotein B-100. J Lipid Res 1992; 33: 369-80
17. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from Framingham Heart Study. Atherosclerosis 2001; 154: 229-36
18. Sakata K, Miho N, Shirotani M, Yoshida H, Takada Y, Tanaka A. Remnant-like particle cholesterol is a major risk factor for myocardial infarction in vasospastic angina with nearly normal coronary artery. Atherosclerosis 1998; 136: 225-31
19. Takeichi S, Yukawa N, Nakajima Y, et al. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. Atherosclerosis 1999; 142: 309-15
20. Kugiyama K, Doi H, Takazoe K, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999; 99: 2858-60
21. Watanabe N, Taniguchi T, Taketof H, Kitagawa Y, Namura H, Yoneda N. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care 1999; 22: 152-6
22. Saito M, Eto M, Kaku K. Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes. Metabolism 2002; 51: 964-9
23. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of c-reactive protein. Circulation 1999; 100: 230-5
24. Watts GF, Dimmitt SB. Fibrates, dyslipoproteinemia and cardiovascular disease. Curr Opin Lipidol 1999; 10: 561-74
25. Takahashi H. High-sensitivity C reactive protein (CRP) assay. A novel method for assessment of risk for atherosclerosis vascular disease. Rinsyo Byori 2002; 50: 30-9
26. Yamada T, Nomata Y, Sugita O, Okada M. A rapid method for measuring serum amyloid A protein by latex agglutination nephelometric immunoassay. Ann Clin Biochem 1993; 30: 72-6
27. Statistical Analysis Systems Institute. Statview Reference Manual. Cary NC: SAS Institute, 1998
28. Temelkova-Kurktschiev T, Siegert G, Bergmann S et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002; 51: 743-9
29. Dawber TR, the Framingham Study. The Epidemiology of Atherosclerotic Disease. Cambridge MA: Harvard University Press, 1980
30. Eto M, Watanabe K, Iwashima Y et al. Apolipoprotein E polymorphism and hyperlipemia in type II diabetics. Diabetes 1986; 35: 1374-82
31. Higashi K, Ito T, Nakajima K, Yonemura A, Nakamura H, Ohsuzu F. Remnant-like particles cholesterol is higher in diabetic patients with coronary artery disease. Metabolism 2001; 50: 1462-5
32. Heinrich PC, Catell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-36
33. Meek RL, Urieli-Shoval S, Benditt ER Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic A function. Proc Natl Acad Sci USA 1994; 91: 3186-90